Current Report · Items 1.01, 3.02, 9.01 · 8-K
GlucoTrack, Inc.
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued pursuant to the Securities Purchase Agreement, dated as of July 14, 2026, by and among th…
Filed Oct 19, 2026Accepted Oct 19, 2026, 4:05 PM EDTCIK 1506983Accession 0001493152-26-047582
Company context
Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Current securities
Historical securities (2)
Registered securities in this filing
GLUCOTRACK, INC. · 8-K · Filed 2026-10-19
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock
- Symbol
- GCTK
- Exchange
- NASDAQ
- Classification
- COMMON
Filing context
Context: AsOf2026-10-13
Dimensions: Not supplied
Accession 000149315226047582 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 1.01, 3.02, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item
1.01. Entry Into a Material Definitive Agreement.
On
October 13, 2026, Glucotrack, Inc. (the “Company”)
entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares
of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued pursuant to the Securities Purchase
Agreement, dated as of July 14, 2026, by and among the Company and the Holders (such agreement, the “Purchase Agreement,”
and such warrants, the “Existing Warrants”). The Waiver was executed by holders constituting the Requisite
Holders (as defined in the Purchase Agreement), as required by Section 11.9 of the Purchase Agreement. The Waiver provides for the waiver
and termination of (i) the restriction under Section 5.10(a) of the Purchase Agreement on the Company’s issuance of, entry into
any agreement to issue, or announcement of the issuance of, shares of Common Stock or Common Stock equivalents (other than exempted securities)
until ninety (90) days following the effectiveness of the registration statement and receipt of the stockholder approval contemplated
thereby, which waiver is effective as to all Holders, and (ii) the exercise price adjustment under Section 3(e) of the Existing Warrants
in connection with any variable rate transaction, which waiver, in accordance with Section 5(m) of the Existing Warrants, is effective
only with respect to the Existing Warrants held by Holders that executed the Waiver.
In
consideration for the Waiver, the Company has become obligated to issue new warrants (the “New Warrants”) to purchase an
aggregate of 406,198 shares of Common Stock (the “Warrant Shares”) to the Holders. The New Warrants have an
exercise price of $7.50 per share, expire five (5) years from the date of issuance, and are not exercisable unless and until the
Company obtains stockholder approval for the issuance of the Warrant Shares in accordance
with Nasdaq Listing Rule 5635. Exercise of the New Warrants is subject to a 9.99% beneficial ownership limitation, and the exercise
price is subject to customary adjustments, subject to a floor price equal to 20% of the closing sale price of the Common Stock on
the date of issuance of the New Warrants. Except as expressly set forth in the Waiver, the Purchase Agreement, the Existing Warrants
and the other transaction documents remain in full force and effect. The foregoing descriptions of the Waiver and the New Warrants
do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Waiver and the form
of New Warrant, which are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item
3.02. Unregistered Sales of Equity Securities.
The
disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference.
The
New Warrants and the Warrant Shares will be issued by the Company to the Holders in reliance upon the exemption from the registration
requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities
Act.
Filed exhibits (1)
EX-4.1 (by filename) ex4-1.htmExhibit
4.1
NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
GLUCOTRACK,
INC.
WARRANT
TO PURCHASE COMMON STOCK
Date
of Issuance: October [__], 2026 (“ Issuance Date ”)
Warrant
Shares: [__]
Glucotrack,
Inc., a Delaware corporation (the “ Company ”), hereby certifies that, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, [__], the registered holder hereof or its permitted assigns (the “ Holder ”)…
Open exhibit ↗